Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azithromycin + cefuroxime is a combination of two antibiotics used together for the treatment of bacterial infections, particularly in cases where broad-spectrum coverage is desired or when mixed infections are suspected. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing the growth and multiplication of susceptible bacteria. Cefuroxime is a second-generation cephalosporin (beta-lactam) antibiotic that acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. This combination may be considered in clinical scenarios such as community-acquired pneumonia or other moderate-to-severe infections where both typical and atypical pathogens are possible[4][6][7]. The use of this specific combination (azithromycin + cefuroxime) is not standard as a fixed-dose product but may be prescribed together based on clinical judgment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + cefuroxime.